In vitro Antibacterial Activity and Resistance Prevention of Antimicrobial Combinations for Dihydropteroate Synthase-Carrying Stenotrophomonas maltophilia

References

• Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:893. doi:10.3389/fmicb.2015.00893
   PubMed Web of Science ®Google Scholar
• Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9(5):312–323. doi:10.1016/S1473-3099(09)70083-0
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol. 2009;4(9):1103–1109. doi:10.2217/fmb.09.84
   PubMed Web of Science ®Google Scholar
• Fratoni AJ, Nicolau DP, Kuti JL. Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints. J Antimicrob Chemother. 2022;77(4):1052–1060. doi:10.1093/jac/dkac018
   Web of Science ®Google Scholar
• Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti-Infect Ther. 2011;9(4):471–488. doi:10.1586/eri.11.24
   PubMed Web of Science ®Google Scholar
• Pollini S, Rossolini GM, Pallecchi L, Andelkovic MV. Antimicrobial treatment of Stenotrophomonas maltophilia invasive infections: systematic review. Antibiotics. 2019;31(6):297–306.
   Google Scholar
• Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis. 2007;13(4):559–565. doi:10.3201/eid1304.061378
   PubMed Web of Science ®Google Scholar
• Al-Jasser AM. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob. 2006;5:23. doi:10.1186/1476-0711-5-23
   PubMedGoogle Scholar
• Zhao J, Xing Y, Liu W, et al. Surveillance of dihydropteroate synthase genes in Stenotrophomonas maltophilia by LAMP: implications for infection control and initial therapy. Front Microbiol. 2016;7:1723. doi:10.3389/fmicb.2016.01723
   Web of Science ®Google Scholar
• Wei C, Ni W, Cai X, Zhao J, Cui J. Evaluation of trimethoprim/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, and ceftazidime alone and in combinations for SXT-susceptible and SXT-resistant Stenotrophomonas maltophilia by in vitro time-kill experiments. PLoS One. 2016;11(3):e0152132. doi:10.1371/journal.pone.0152132
   PubMed Web of Science ®Google Scholar
• Garazi M, Singer C, Tai J, Ginocchio CC. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect. 2012;81(2):114–118. doi:10.1016/j.jhin.2012.02.008
   PubMed Web of Science ®Google Scholar
• Dizbay M, Shah MD, Coe KE, et al. Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. Turk J Med Sci. 2019;74(7):2055–2059.
   Google Scholar
• Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis. 2007;44(5):681–688. doi:10.1086/511642
   PubMed Web of Science ®Google Scholar
• Whitby PW, Carter KB, Burns JL, Royall JA, LiPuma JJ, Stull TL. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J Clin Microbiol. 2000;38(12):4305–4309. doi:10.1128/JCM.38.12.4305-4309.2000
   Web of Science ®Google Scholar
• Zhao J, Liu Y, Liu Y, et al. Frequency and genetic determinants of tigecycline resistance in clinically isolated Stenotrophomonas maltophilia in Beijing, China. Front Microbiol. 2018;9:549. doi:10.3389/fmicb.2018.00549
   PubMed Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne: Clinical and Laboratory Standards Institute; 2021
   Google Scholar
• Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother. 2014;58(3):1757–1762. doi:10.1128/AAC.00741-13
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005;52(3):165–171. doi:10.1016/j.diagmicrobio.2005.05.006
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy. 2001;21(10 Pt 2):233S–252S. doi:10.1592/phco.21.16.233s.33992
   Web of Science ®Google Scholar
• Guglielmo BJ, Flaherty JF, Batman R, Barriere SL, Gambertoglio JG. Comparative pharmacokinetics of low- and high-dose ticarcillin. Antimicrob Agents Chemother. 1986;30(3):359–360. doi:10.1128/AAC.30.3.359
   Web of Science ®Google Scholar
• Jaresko GS, Barriere SL, Johnson BL Jr. Serum and blister fluid pharmacokinetics and bactericidal activities of ampicillin-sulbactam, cefotetan, cefoxitin, ceftizoxime, and ticarcillin-clavulanate. Antimicrob Agents Chemother. 1992;36(10):2233–2238. doi:10.1128/AAC.36.10.2233
   PubMed Web of Science ®Google Scholar
• Burgess DS, Frei CR. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother. 2005;56(5):893–898. doi:10.1093/jac/dki335
   Web of Science ®Google Scholar
• Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian V, editor. Antibiotics in Laboratory Medicine. 5th ed. Philadelphia: The Lippincott Williams & Wilkins Co.; 2005:365–440.
   Google Scholar
• Ni W, Cui J, Liang B, et al. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii. J Antibiot. 2013;66(12):705–708. doi:10.1038/ja.2013.84
   PubMed Web of Science ®Google Scholar
• Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;33(suppl 3):S147–S156. doi:10.1086/321841
   PubMed Web of Science ®Google Scholar
• Wei C, Ni W, Cai X, Cui J, Monte A. Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia. Infect Dis. 2015;47(12):846–851. doi:10.3109/23744235.2015.1064542
   PubMed Web of Science ®Google Scholar
• Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother. 2003;52(1):11–17. doi:10.1093/jac/dkg269
   Web of Science ®Google Scholar
• Cho SY, Lee DG, Choi SM, et al. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. BMC Infect Dis. 2015;15:69. doi:10.1186/s12879-015-0801-7
   PubMed Web of Science ®Google Scholar
• Sarzynski SH, Warner S, Sun J, et al. Trimethoprim-sulfamethoxazole versus levofloxacin for Stenotrophomonas maltophilia infections: a retrospective comparative effectiveness study of electronic health records from 154 US hospitals. Open Forum Infect Dis. 2022;9(2):ofab644. doi:10.1093/ofid/ofab644
   PubMed Web of Science ®Google Scholar
• Watson L, Esterly J, Jensen AO, Postelnick M, Aguirre A, McLaughlin M. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections. J Glob Antimicrob Resist. 2018;12:104–106. doi:10.1016/j.jgar.2017.09.015
   PubMed Web of Science ®Google Scholar
• Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58(1):176–182. doi:10.1128/AAC.01324-13
   PubMed Web of Science ®Google Scholar
• Wang A, Wang Q, Kudinha T, Xiao S, Zhuo C. Effects of fluoroquinolones and azithromycin on biofilm formation of Stenotrophomonas maltophilia. Sci Rep Sci Rep. 2016;6:29701. doi:10.1038/srep29701
   PubMed Web of Science ®Google Scholar
• Pompilio A, Catavitello C, Picciani C, et al. Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis. J Med Microbiol. 2010;59(1):76–81. doi:10.1099/jmm.0.011981-0
   Web of Science ®Google Scholar
• Di Bonaventura G, Spedicato I, D’Antonio D, Robuffo I, Piccolomini R. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother. 2004;48(1):151–160. doi:10.1128/AAC.48.1.151-160.2004
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Karnesis L, Galani I, Giamarellou H. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 2002;46(12):3997–3999. doi:10.1128/AAC.46.12.3997-3999.2002
   Web of Science ®Google Scholar
• Chang YT, Lin CY, Lu PL, et al. Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections. J Microbiol Immunol Infect. 2014;47(1):28–35. doi:10.1016/j.jmii.2012.08.014
   Google Scholar
• Pien CJ, Kuo HY, Chang SW, et al. Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital. J Microbiol Immunol Infect. 2015;48(3):291–295. doi:10.1016/j.jmii.2013.09.005
   Google Scholar
• Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999;43(supplB):83–90. doi:10.1093/jac/43.suppl_2.83
   Web of Science ®Google Scholar